1. Scrip
  2. >>Business

Genentech Places Bet On Polymer Nanoparticle-Based Delivery With GenEdit Deal

 
• By Alaric DeArment

Deal Snapshot: The Roche subsidiary will use GenEdit’s hydrophilic nanoparticles to develop genetic medicines for autoimmune diseases meant to overcome the limitations of existing delivery methods.

• Source: Shutterstock

Who: Roche Holding AG’s Genentech, Inc. /GenEdit Inc.

What: Genentech will partner with GenEdit to discover hydrophilic nanoparticles for the development of nucleic acid-based medicines for autoimmune diseases.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business